CRANBURY, N.J., April 30,
2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE
American: PTN), a biopharmaceutical company developing
first-in-class medicines based on molecules that modulate the
activity of the melanocortin receptor system, today announced it
will host a virtual KOL event on Wednesday,
May 8, 2024 at 10:00 AM ET. To
register, click here.
The event will feature Jesse
Richards, DO (Oklahoma State
University College of Osteopathic Medicine), who will
discuss the current treatment landscape for obesity, the need for
new treatments with alternative mechanisms of action and how
combining a melanocortin agonist with incretins can optimize
treatment.
The event will focus on the Company's metabolic program
evaluating novel selective melanocortin receptor 4 agonists (MCR4)
as a treatment for obesity in combination with a GLP-1 agonist.
Palatin's Phase 2 clinical study is targeted to start mid-calendar
year 2024, with topline data readout expected by the end of
calendar year 2024.
A live question and answer session will follow the formal
presentation.
About Jesse Richards,
DO
Jesse Richards, DO earned
his Doctor of Osteopathic Medicine degree from the Oklahoma State University College of Osteopathic
Medicine in Tulsa, OK in 2016, and
completed his residency at the University Kansas School of Medicine
in Kansas City, KS in 2019.
Board-certified in internal medicine and obesity medicine, Dr.
Richards is the director of obesity medicine in the bariatric
section and assistant professor of the department of internal
medicine for the University of Oklahoma
in Tulsa, OK.
About Melanocortin Receptor 4 Agonists Effect on
Obesity
Genetic analysis has identified the melanocortin
receptor 4 (MCR4) of the paraventricular nucleus of the
hypothalamus as playing a central role in appetite regulation.
Genetic mutations that inhibit signaling in the MCR4 pathway lead
to hyperphagia, decreased energy expenditure and early-onset
obesity; such mutations have been identified as the cause of
several rare genetic obesity disorders. Agouti-related peptide is
an endogenous antagonist of the MCR4 that works with neuropeptide Y
to stimulate appetite, whereas MCR4 agonists such as α- and
β-melanocyte-stimulating hormone promote satiety. Agonism of the
MCR4 therefore represents an attractive target for potential
obesity treatments.
About Obesity
Obesity, which is defined as a body mass
index (BMI) ≥30 kg/m2, represents a rising worldwide public health
concern. Obesity is associated with an increased risk of overall
mortality and serious health conditions, including high blood
pressure, high cholesterol, type 2 diabetes, coronary heart
disease, stroke and certain cancers. Health-related quality of life
is significantly lower among adults with obesity, and obesity is
associated with increased health care resource use and high
economic burden. Safe and effective obesity treatments therefore
remain a critical unmet need. The global increase in the prevalence
of obesity is a public health issue that has severe cost
implications to healthcare systems. In the United States, about 42% of adults live
with obesity, and one out of five teens between the ages of 12-19
live with obesity.
About Palatin
Palatin is a biopharmaceutical company
developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin receptor systems, with
targeted, receptor-specific product candidates for the treatment of
diseases with significant unmet medical need and commercial
potential. Palatin's strategy is to develop products and then form
marketing collaborations with industry leaders to maximize their
commercial potential. To learn more about Palatin, please visit us
on www.Palatin.com and follow us on Twitter at
@PalatinTech.
Forward-looking Statements
Statements in this press
release that are not historical facts, including statements about
future expectations of Palatin Technologies, Inc., such as
statements about Palatin products in development, clinical trial
results, potential actions by regulatory agencies including the
FDA, regulatory plans, development programs, proposed indications
for product candidates, and market potential for product candidates
are "forward-looking statements" within the meaning of Section 27A
of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and as that term is defined in the Private
Securities Litigation Reform Act of 1995. Palatin intends that such
forward-looking statements be subject to the safe harbors created
thereby. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that could cause Palatin's
actual results to be materially different from its historical
results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and other regulatory agencies
and the need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory
approvals, products developed by competing pharmaceutical,
biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating events that
occur after the date of this press release.
Palatin Technologies® is a registered trademark of
Palatin Technologies, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-to-host-virtual-kol-event-beyond-glps-the-multiple-roles-for-novel-melanocortin-receptor-4-agonists-in-treating-obesity-and-weight-loss-maintenance-on-may-8-2024-302131150.html
SOURCE Palatin Technologies, Inc.